跳至主要内容
临床试验/NCT01798914
NCT01798914
No Longer Available
不适用

Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder

Mannkind Corporation14 个研究点 分布在 1 个国家2008年10月

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Type 1 Diabetes
发起方
Mannkind Corporation
试验地点
14
状态
No Longer Available
最后更新
10年前

概览

简要总结

The purpose of this study is to allow patients with specific needs for inhaled insulin to continue with inhaled insulin therapy using Technosphere Insulin after Exubera was withdrawn from the market.

详细描述

A Phase 3, open label, multicenter, safety follow up trial to convert the treatment of subjects currently using Exubera to treatment with TI Inhalation Powder

注册库
clinicaltrials.gov
开始日期
2008年10月
结束日期
2015年5月
最后更新
10年前
研究类型
Expanded Access
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Subject has type 1 or type 2 diabetes mellitus and is currently being treated with or has been treated with Exubera.
  • Subject has a severe phobia to sc injections of insulin (needle phobia) preventing conventional treatment OR has impaired sc insulin absorption

排除标准

  • Smoking in the previous 6 months
  • History of asthma or chronic obstructive pulmonary disease (COPD) or any other significant pulmonary disease, or exposure to pulmonary toxins.
  • Clinically significant pulmonary abnormalities on chest high-resolution computed tomography (HRCT).
  • PFT results prior to transferring to TI Inhalation Powder showing any of the following: FEV1 \< 70% of predicted, FVC \< 70% of predicted, DLCO \< 70% of predicted, TLC \< 80% of predicted.
  • Allergy to insulin

结局指标

主要结局

未指定

研究点 (14)

Loading locations...

相似试验